Sectoral Asset Management Inc Arcutis Biotherapeutics, Inc. Transaction History

Sectoral Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$5.31 - $10.98 $52,728 - $109,031	-9,930 Reduced 69.5%	4,357 $23,000
Q2 2023 Aug 11, 2023	SELL	$7.51 - $15.0 $2.27 Million - $4.54 Million	-302,865 Reduced 95.5%	14,287 $136,000
Q1 2023 May 12, 2023	BUY	$10.23 - $17.14 $1.16 Million - $1.94 Million	113,300 Added 55.58%	317,152 $3.49 Million
Q4 2022 Feb 10, 2023	SELL	$13.96 - $20.4 $239,176 - $349,513	-17,133 Reduced 7.75%	203,852 $3.02 Million
Q3 2022 Nov 10, 2022	BUY	$17.85 - $26.95 $731,296 - $1.1 Million	40,969 Added 22.76%	220,985 $4.22 Million

Q2 2022 Aug 15, 2022	SELL	$16.33 - $22.2 $638,829 - $868,464	-39,120 Reduced 17.85%	180,016 $3.84 Million
Q1 2022 May 10, 2022	SELL	$14.38 - $22.79 $353,748 - $560,634	-24,600 Reduced 10.09%	219,136 $4.22 Million
Q4 2021 Feb 11, 2022	SELL	$14.98 - $25.5 $7.72 Million - $13.1 Million	-515,027 Reduced 67.88%	243,736 $5.06 Million
Q2 2021 Aug 16, 2021	SELL	$24.42 - $34.75 $2.93 Million - $4.18 Million	-120,185 Reduced 13.67%	758,763 $20.7 Million
Q1 2021 May 14, 2021	BUY	$24.47 - $36.98 $21.5 Million - $32.5 Million	878,948 New	878,948 $25.4 Million

172

126M

498K

1.64M

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Sectoral Asset Management Inc with notifications on news.